Last reviewed · How we verify
Quinvaxem
At a glance
| Generic name | Quinvaxem |
|---|---|
| Also known as | Whole cell pertussis containing vaccine |
| Sponsor | Universiteit Antwerpen |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand (PHASE4)
- A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject (PHASE3)
- Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B (PHASE3)
- Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quinvaxem CI brief — competitive landscape report
- Quinvaxem updates RSS · CI watch RSS
- Universiteit Antwerpen portfolio CI